GLP-1 and Thyroid Health: Ozempic Thyroid Cancer Risk Nodules and What You Should Know

May 24, 2026

GLP-1 and Thyroid Health: Ozempic Thyroid Cancer Risk, Nodules, and What You Should Know

By Dr. Onikepe Adegbola, MD PhD — Johns Hopkins-trained physician-scientist and founder of Casa de Sante

Key Takeaways

GLP-1 medications carry a black box warning for medullary thyroid carcinoma (MTC) based on rodent studies — but the clinical significance in humans remains uncertain
Rats developed thyroid C-cell tumors at doses 8-34x higher than human doses. Mice did not. Primates did not. Humans have far fewer C-cells than rats.
Real-world data from millions of prescriptions has NOT shown an increased rate of thyroid cancer in humans taking GLP-1 medications
GLP-1 medications are absolutely contraindicated in patients with personal or family history of MTC or MEN2 (multiple endocrine neoplasia type 2)
Routine thyroid monitoring beyond standard care is NOT recommended for most GLP-1 patients

The Science Behind the Warning

What Happened in Rats

During preclinical testing, rats exposed to liraglutide and semaglutide developed C-cell hyperplasia and medullary thyroid carcinoma. This was dose-dependent and time-dependent. The FDA required a black box warning — the strongest safety warning — based on these findings.

Why Rats Are Different

C-cell density: Rats have significantly more thyroid C-cells than humans. Rats: 5-10% of thyroid cells. Humans: <1%.
GLP-1 receptors on C-cells: Rat C-cells express high levels of GLP-1 receptors. Human C-cells express minimal GLP-1 receptors.
Calcitonin response: GLP-1 stimulates calcitonin release from rat C-cells. In human studies, semaglutide does NOT increase serum calcitonin levels.
Dose equivalence: The rat doses that caused tumors were 8-34x human equivalent doses, given for the rats' entire lifetime (2 years).

Human Data

SUSTAIN/STEP clinical trials: No increase in thyroid cancer across all semaglutide trials (thousands of patients, up to 2 years of follow-up).
EPI-PHARE French cohort study (2024): 2.5 million patients on GLP-1 medications. No increased risk of thyroid cancer overall. A small signal for "all thyroid cancers" was found but was not statistically significant after adjustments, and specifically no MTC signal.
FAERS database: FDA adverse event reporting shows no disproportionate MTC signal for GLP-1 medications compared to other diabetes drugs.

Who Should NOT Take GLP-1 Medications

Personal history of MTC: Absolute contraindication
Family history of MTC: Absolute contraindication
MEN2 (Multiple Endocrine Neoplasia type 2): Absolute contraindication — this genetic syndrome includes MTC
Unexplained thyroid nodule with elevated calcitonin: Evaluate the nodule BEFORE starting GLP-1

Practical Guidance

Tell your prescriber about any thyroid history: Prior thyroid nodules, family history of thyroid cancer, or MEN2 in the family.
Know the symptoms of thyroid cancer: Lump or swelling in the neck, difficulty swallowing, hoarseness that does not resolve, persistent neck pain. Report these to your doctor promptly — they are likely NOT caused by your GLP-1 medication, but should be evaluated.
Routine monitoring: Checking thyroid ultrasound or calcitonin levels specifically because of GLP-1 use is NOT recommended by endocrine guidelines. Continue standard thyroid screening per your doctor's usual practice.
Do not stop your GLP-1 because of the warning: The black box warning exists because the FDA required it based on animal data. The benefits of weight loss and metabolic improvement far outweigh the theoretical thyroid risk for the vast majority of patients.

🛒 Thyroid & Overall Health Support

Daily Vitamin — Selenium, zinc, and iodine are critical for thyroid function. Many patients on GLP-1 have suboptimal micronutrient intake due to reduced appetite. A comprehensive vitamin ensures thyroid-supporting nutrients are not depleted.
Whey Protein — Adequate protein supports thyroid hormone synthesis (T3 and T4 are amino acid-based hormones). Protein intake matters for every hormonal system.

Medical Disclaimer: This article is for educational purposes only. Do not modify your GLP-1 medication regimen based on this article. Discuss thyroid concerns with your endocrinologist or prescriber. Dr. Adegbola is the founder of Casa de Sante.

Back to blog

Keto. Paleo. No Digestive Triggers. Shop Now

No onion, no garlic – no pain. No gluten, no lactose – no bloat. Low FODMAP certified.

Stop worrying about what you can't eat and start enjoying what you can. No bloat, no pain, no problem.

Our gut friendly keto, paleo and low FODMAP certified products are gluten-free, lactose-free, soy free, no additives, preservatives or fillers and all natural for clean nutrition. Try them today and feel the difference!

Country/region